GNS Healthcare completes $23 million D-round financing

July 9, GNS Healthcare (GNS) completed a $23 million round of D financing. The round of financing was led by Cigna Ventures, amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, and Gary Loveman, former CEO of Caesar and president of Aetna' division. GNS Healthcare intends to use this money to expand its AI-based data analytics business.
GNS Healthcare (GNS) is a medical data analytics company founded in 2000 and headquartered in Cambridge, Massachusetts, USA. Led by Colin Hill, chairman, chief executive and co-founder, the company focuses on applying and advancing big data analytics to help healthcare providers meet the challenges of care, treatment and healthcare costs. GNS has a multidisciplinary group of physicists, actuary, geneticists, engineers, computer scientists and business elites to solve medical resource matching problems for health insurance, biopharmaceutical companies and health systems, using a large and diverse stream of data for precise treatment and personal care management.
GNS partners with leading biopharmaceutical companies to accelerate and optimize their drug discovery, development and commercialization processes. The company's platform uses clinical trial data and real-world data (RWD) to simulate patient treatment effectiveness, from which pharmaceutical companies can accurately observe the various responses of the patient sub-group and derive the reasons for the response. These models can also be used to simulate clinical trials to generate real-world evidence of the efficacy of drugs in the real world. GNS also works with innovative health insurance companies to determine when medical institutions in insurance plans should implement what drug and care interventions enable insurers to assess the effectiveness of interventions. In addition, GNS worked with foundations, academic and research institutions to accelerate drug development by assisting in the discovery of new disease treatment options and drug targets.GNS's causal machine learning model REFS (Reverse Engineering and Forward Simulation, Reverse Engineering and Forward Simulation) goes beyond data correlation analysis to infer causality between variables. Significantly improve patient health and reduce the total cost of care by transforming diverse data streams to develop treatment options and care interventions for individuals. The company has developed learning models for more than 40 diseases in the fields of oncology, cardiovascular and metabolism, neurology, autoimmune, and more.About Cigna VenturesCigna Ventures is a wholly owned venture capital subsidiary of Cigna Group headquartered in Connecticut, USA. The company is committed to accelerating the growth of healthcare start-ups, investing primarily in digital health and retail, nursing and management.About Amgen VenturesFounded in 2004 and headquartered in San Francisco, California, with offices in Washington State, Cambridge, Massachusetts, etc. The company is a venture capital firm owned by Amgen and is mainly involved in the early and late stages of investment in North American, European and UK companies. Amgen Ventures focuses on biotechnology, covering oncology, inflammation, hematology, kidney disease, metabolic disorders, neuroscience and cardiovascular therapy. The company typically invests between $2 million and $3 million, with a maximum investment of $10 million.About CelgeneCelgene is a global integrated biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies aimed at treating cancer and immune inflammation. The company is currently working on a combination of drugs to treat hematological and solid tumors, including multiple myeloma (MM), myeloid hyperplate syndrome (MDS), chronic lymphoblastic leukemia (CLL), non-Hodgkin's lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.About Echo Health VenturesFounded in 2016 and headquartered in Seattle, Washington, USA, with offices in Oregon, USA and Durham, UK. As a private equity and venture capital firm, Echo Health Ventures is committed to helping build leading healthcare companies that are primarily involved in early and late stages of their investments.About Alexandria Venture InvestmentsAlexandria Ventures is a strategic venture capital unit of Alexandria Real Estate Equities, headquartered in San Francisco, California, USA. The company focuses on innovative life sciences companies that invest in breakthrough technologies and therapies, and is primarily involved in seeding, early and long-term investments. (Arterial mesh)